Cannabis Science Confirms Receipt of Issued US Patent Number 9,763,991 For Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, Sleep Deprivation (Insomnia), Anxiety Disorders (ADHD), and (PTSD)
IRVINE, CA, Oct. 29, 2018 (GLOBE NEWSWIRE) --
Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to confirm receipt of Issued US Patent Number 9,763,991 For Compositions of Cannabinol (CBN) for Treatment of Various Neurobehavioral Disorders, Sleep Deprivation (Insomnia), Anxiety Disorders (ADHD), and Post-Traumatic Stress Disorders (PTSD), among other target indications.
The invention relates to a composition for use in the treatment of neurobehavioral disorders utilizing various Cannabis plant extracts comprising Cannabinol (CBN) preferably with other constituents of this plant for such use and a method for the extraction of plants. The plants or plant parts may for instance be derived from Cannabis Sativa and/or Cannabis Indica and/or Cannabis ruderalis and/or other elements, and mixtures thereof. The plant extracts derived showed particularly beneficial effects against Sleeping Disorders, in particular Insomnia, Post-Traumatic Stress Disorder (PTSD), and anxiety disorders including Attention Deficit Hyperactivity Disorder (ADHD).
PTSD is becoming one of the most international wide-spread pandemic conditions; in the Military it seems to be causing a chain reaction, in families it seems to be causing mass confusion to the triggers, in children it is a mystery staring us right in the face. Internationally, PTSD is one of the main reasons insomnia and ADHD has spread prolifically.
In U.S.A. alone, statistic has shown that there are over 50 million people with chronic sleep disorders, plus 20 million people with occasional sleep disorders. Most of these people use some form of prescription drugs or Melatonin to help their sleep disorders. However, some common FDA approved treatments and drugs have advertised side effects, such as daytime drowsiness, depressed mood, feeling irritable, stomach pain, headache, dizziness, breast enlargement in men, decreased sperm count in men, etc. There are definitely a sufficient number of people with demand to help their sleep disorders without the side effects of these other types of harmful solutions.
From the United States a Direct Quote from the NIH:
PTSD is a disorder that develops in some people who have experienced a shocking, scary, or dangerous event.
It is natural to feel afraid during and after a traumatic situation. Fear triggers many split-second changes in the body to help defend against danger or to avoid it. This “fight-or-flight” response is a typical reaction meant to protect a person from harm. Nearly everyone will experience a range of reactions after trauma, yet most people recover from initial symptoms naturally. Those who continue to experience problems may be diagnosed with PTSD. People who have PTSD may feel stressed or frightened even when they are not in danger.
Please click this link to read the full report:
From Canada a Direct quote from the CDMA:
Frightening situations happen to everyone at some point. People can react in many different ways: they might feel nervous, have a hard time sleeping well, or go over the details of the situation in their mind. These thoughts or experiences are a normal reaction. They usually decrease over time and the people involved can go back to their daily lives. Post-traumatic stress disorder, on the other hand, lasts much longer and can seriously disrupt a person’s life.
Post-traumatic stress disorder (PTSD) is a mental illness. It involves exposure to trauma involving death or the threat of death, serious injury, or sexual violence.
Something is traumatic when it is very frightening, overwhelming and causes a lot of distress. Trauma is often unexpected, and many people say that they felt powerless to stop or change the event. Traumatic events may include crimes, natural disasters, accidents, war or conflict, or other threats to life. It could be an event or situation that you experience yourself or something that happens to others, including loved ones.
PTSD causes intrusive symptoms such as re-experiencing the traumatic event. Many people have vivid nightmares, flashbacks, or thoughts of the event that seem to come from nowhere. They often avoid things that remind them of the event—for example, someone who was hurt in a car crash might avoid driving.
Please click this link to read the full Report:
Cannabis Science will immediately go into commercial production in various markets depending on regulatory environment and approvals. The Company is making various supplement combinations with CBN targeting Sleep Disorder and PTSD. The Company will aggressively license partners to develop the supplements for mass distribution with the right fit larger and smaller organizations, including pharmaceutical firms, biotech development firms, and distribution/sales organizations. The Company has begun negotiations in the United States and Canada and expects a great revenue stream to help fuel the rest of its international drug development and economic development programs.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, the characterization of medicines, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward-looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company's reports filed with the Securities and Exchange Commission.